Genprex Inc

GNPX

Company Profile

  • Business description

    Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

  • Contact

    3300 Bee Cave Road
    Suite 650-227
    AustinTX78746
    USA

    T: +1 877 774-4679

    https://www.genprex.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    15

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,768.601.60-0.02%
CAC 407,825.9621.290.27%
DAX 4024,350.9974.510.31%
Dow JONES (US)42,427.7491.90-0.22%
FTSE 1008,807.946.650.08%
HKSE23,885.67231.640.98%
NASDAQ19,460.4961.530.32%
Nikkei 22537,554.49192.96-0.51%
NZX 50 Index12,577.1582.440.66%
S&P 5005,970.810.440.01%
S&P/ASX 2008,538.902.90-0.03%
SSE Composite Index3,384.107.900.23%

Market Movers